$2.46 0.4%
BDTX Stock Price vs. AI Score
Data gathered: December 4

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers.


Black Diamond Therapeutics
Price $2.46
Target Price Sign up
Volume 476,720
Market Cap $147M
Year Range $2.43 - $7.39
Dividend Yield 0%
Analyst Rating 100% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '24990,0005.2M-4.2M-16M-18M-0.275
Q2 '24620,0009.6M-9M-20M-22M-0.360
Q1 '24460,0006.7M-6.2M-18M-20M-0.350
Q4 '23330,0005.6M-5.2M-19M-21M-0.340
Q3 '23330,0007.9M-7.5M-23M-24M-0.450

Insider Transactions View All

Versant Venture Capital VI, L.P. filed to sell 3,726,341 shares at $6.3.
August 30 '24
BB BIOTECH AG filed to buy 8,517,839 shares at $2.3.
October 19 '23
RA Capital Healthcare Fund LP filed to buy 3,213,828 shares at $5.
July 7 '23
Behbahani Ali filed to buy 4,448,757 shares at $5.
July 6 '23
BB BIOTECH AG filed to buy 8,117,839 shares at $5.
July 3 '23

What is the Market Cap of Black Diamond Therapeutics?

The Market Cap of Black Diamond Therapeutics is $147M.

What is the current stock price of Black Diamond Therapeutics?

Currently, the price of one share of Black Diamond Therapeutics stock is $2.46.

How can I analyze the BDTX stock price chart for investment decisions?

The BDTX stock price chart above provides a comprehensive visual representation of Black Diamond Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Black Diamond Therapeutics shares. Our platform offers an up-to-date BDTX stock price chart, along with technical data analysis and alternative data insights.

Does BDTX offer dividends to its shareholders?

As of our latest update, Black Diamond Therapeutics (BDTX) does not offer dividends to its shareholders. Investors interested in Black Diamond Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Black Diamond Therapeutics?

Some of the similar stocks of Black Diamond Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.